Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3;80(9):2550-2552.
doi: 10.1093/jac/dkaf193.

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient

Giovanni Mulé  1 , Giulia Coniglione  1   2 , Milo Gatti  3   4 , Andrea Cona  1 , Giuseppina Di Martino  5 , Giusy Ranucci  6 , Jean de Ville de Goyet  6 , Federico Pea  3   4 , Alessandra Mularoni  1
Affiliations

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient

Giovanni Mulé et al. J Antimicrob Chemother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Temperature and CRP trends and changes in therapy. M/V = meropenem/vaborbactam; EI = extended infusion; FOS = fosfomycin.
See this image and copyright information in PMC

References

    1. Chiotos K, Hayes M, Gerber JS et al. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc 2019; 9: 56–66. 10.1093/jpids/piz085 - DOI - PMC - PubMed
    1. EMA—European Medicines Agency . https://www.ema.europa.eu/en/homepage.
    1. Tumbarello M, Raffaelli F, Giannella M et al. Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study. Open Forum Infect Dis 2024; 11: ofae273. 10.1093/ofid/ofae273 - DOI - PMC - PubMed
    1. Barone R, Conti M, Giorgi B et al. Fast and sensitive method for simultaneous quantification of meropenem and vaborbactam in human plasma microsamples by liquid chromatography–tandem mass spectrometry for therapeutic drug monitoring. Antibiotics 2023; 12: 719. 10.3390/antibiotics12040719 - DOI - PMC - PubMed
    1. Griffith DC, Loutit JS, Morgan EE et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother 2016; 60: 6326–32. 10.1128/AAC.00568-16 - DOI - PMC - PubMed